1. Home
  2. ERNAW vs AGNCM Comparison

ERNAW vs AGNCM Comparison

Compare ERNAW & AGNCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.07

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock

AGNCM

AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock

N/A

Current Price

$25.27

Market Cap

0.0

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
ERNAW
AGNCM
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
ERNAW
AGNCM
Price
$0.07
$25.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.7K
10.5K
Earning Date
N/A
01-26-2026
Dividend Yield
N/A
8.99%
EPS Growth
31.29
58.06
EPS
N/A
0.37
Revenue
$582,000.00
N/A
Revenue This Year
N/A
$13.57
Revenue Next Year
N/A
$63.17
P/E Ratio
N/A
$68.24
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$23.63
52 Week High
$0.23
$25.29

Technical Indicators

Market Signals
Indicator
ERNAW
AGNCM
Relative Strength Index (RSI) 52.88 62.40
Support Level $0.03 $24.80
Resistance Level $0.10 N/A
Average True Range (ATR) 0.02 0.08
MACD 0.00 0.01
Stochastic Oscillator 69.21 100.00

Price Performance

Historical Comparison
ERNAW
AGNCM

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

About AGNCM AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock

AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.

Share on Social Networks: